Ipilimumab-Induced Enteritis without Colitis: A New Challenge

INTRODUCTION: Ipilimumab is an immune checkpoint inhibitor targeting cytotoxic T-lymphocyte associated antigen 4 (CTLA4), approved to treat metastatic melanoma. It was the first therapy shown to prolong survival in a large, randomized clinical trial. However, immune-related adverse events are common...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Case Rep Oncol
Egile Nagusiak: Messmer, Marcus, Upreti, Sunita, Tarabishy, Yaman, Mazumder, Nikhilesh, Chowdhury, Reezwana, Yarchoan, Mark, Holdhoff, Matthias
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: S. Karger AG 2016
Gaiak:
Case Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5126596/
https://ncbi.nlm.nih.gov/pubmed/27920706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000452403
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak